Magdalena Masiejczyk

Statistics

Publications

Citations

194

H-Index

Active since

2017

Affiliations

The Maria Sklodowska-Curie National Research Institute of Oncology(Current)

Postgraduate School of Molecular Medicine

Magdalena Masiejczyk is an author at The Maria Sklodowska-Curie National Research Institute of Oncology specializing in pharmacology, medicine, and inflammatory cell signaling.

Publications per year

2017–2021

Publications

SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains

Tomasz Rzymski, Michał Mikuła, Eliza Żyłkiewicz et al. · Oncotarget · 2017 · 107 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses

Fan Huang, Christophe Gonçalves, Margarita Bartish et al. · Journal of Clinical Investigation · 2021 · 65 citations · Full text

Medicine, Immunology, Oncology +17

Selective Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibition by the SCH772984 Compound Attenuates In Vitro and In Vivo Inflammatory Responses and Prolongs Survival in Murine Sepsis Models

Michał Kopczyński, Izabela Rumieńczyk, Maria Kulecka et al. · International Journal of Molecular Sciences · 2021 · 22 citations · Full text

Veterinary Medicine, Pharmacology, Pharmacotherapy +17

1–3 of 3